Please use this identifier to cite or link to this item:
|Title:||The minimal clinically important difference in the treadmill six-minute walk test in active women with breast cancer during and after oncological treatments.||Austin Authors:||Cantarero-Villanueva, Irene;Postigo-Martin, Paula;Granger, Catherine L ;Waterland, Jamie;Galiano-Castillo, Noelia;Denehy, Linda||Affiliation:||Institute for Breathing and Sleep
Health Sciences Faculty, University of Granada, Spain..
Department of Physiotherapy, School of Health Sciences, The University of Melbourne, Melbourne, Australia..
Department of Physiotherapy, the Royal Melbourne Hospital, Melbourne, Australia..
GDipPhysioCardio, BAppScPhysio, Melbourne School of Health Sciences, The University of Melbourne, Melbourne, VIC, Australia..
Allied Health Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia..
Sport and Health Research Center (IMUDs), Granada, Spain..
Instituto de Investigación Biomédica (ibs.GRANADA), Granada, Spain..
|Issue Date:||30-Mar-2022||metadata.dc.date:||2022||Publication information:||Disability and Rehabilitation 2023; 45(5)||Abstract:||To examine the minimal clinically important difference (MCID) in the treadmill 6-minute walk test (6MWT) in women with breast cancer. A secondary analysis of cross-sectional data from 112 women who were undergoing chemotherapy or had undergone anticancer treatment was conducted. Participants completed the 6MWT on a treadmill and the European Organization for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30) twice, eight weeks apart. Change in the physical function domain of the EORTC-QLQ-C30 was used to classify the "positive change" subgroup (≥5 points difference) and the "unchanged" subgroup (<5 points difference). This was combined with the distance difference from the 6MWTs, determining the MCID as the cut-off from the area under the receiver operating characteristic (AUROC) curve (anchor-based determination). The MCID was also determined from (1) the effect size and (2) the difference in standard error (SEM) of the results of the first and second 6MWT (distribution-based determination). The MCIDs in the during-chemotherapy group was 66.5 and 41.5 m and those in the after-treatment group to be 41.4 and 40.5 m (SEM and effect size based respectively). The MCID in the treadmill 6MWT distance could be used to interpret changes in the physical health status of women with breast cancer.IMPLICATIONS FOR REHABILITATIONThe MCID for the 6MWT on treadmill in active women with breast cancer is of approximately 54 m during chemotherapy, and 41.6 m after treatment.The MCID on treadmill 6MWT distance could be used to interpret a decline in the physical health status of women with breast cancer.The 6MWT on treadmill could be an easy, feasible, performed under controlled conditions, alternative to the 6MWT to obtain valuable information in this population.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/29681||DOI:||10.1080/09638288.2022.2043461||ORCID:||0000-0002-3834-1711
|Journal:||Disability and rehabilitation||PubMed URL:||35352996||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/35352996/||Type:||Journal Article||Subjects:||6MWT
minimal clinically important difference
|Appears in Collections:||Journal articles|
Show full item record
checked on May 29, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.